SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2183843

Cover Image

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2183843

Circular RNA-Based Therapeutics Market Forecasts to 2034 - Global Analysis By Therapeutic Modality, Technology, Delivery Method, Route of Administration, Application, End User and By Geography

PUBLISHED:
PAGES: 300+ Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4150
PDF (2-5 User License)
USD 5250
PDF & Excel (Site License)
USD 6350
PDF & Excel (Global Site License)
USD 7500

Add to Cart

According to Stratistics MRC, the Global Circular RNA-Based Therapeutics Market is accounted for $0.3 billion in 2026 and is expected to reach $2.5 billion by 2034 growing at a CAGR of 30.3% during the forecast period. The Circular RNA-Based Therapeutics Market encompasses emerging therapeutic platforms utilizing engineered circular RNA molecules to enable sustained protein expression, immune modulation, and targeted cellular engineering. Increasing investment in RNA medicine, growing demand for innovative treatments, and advancements in nucleic acid delivery technologies are supporting market development. Innovations in RNA circularization, translation enhancement, and lipid nanoparticle formulations improve therapeutic potential. Expanding biotechnology partnerships and clinical research initiatives create additional growth opportunities.

Market Dynamics:

Driver:

Increasing investment in RNA therapeutics and demand for sustained protein expression

Increasing investment in RNA therapeutics and demand for sustained protein expression is driving market growth. Circular RNA molecules possess covalently closed structures that can provide greater resistance to exonuclease degradation than conventional linear RNA. This characteristic offers potential advantages for prolonged therapeutic protein production and reduced dosing frequency. Advancements in RNA circularization, internal ribosome entry sites, and translation optimization improve platform capabilities. Growing pharmaceutical investment in programmable medicines and next-generation nucleic acid therapeutics further supports research and development activities.

Restraint:

Complex manufacturing processes and limited clinical validation of circular RNA therapies

Complex manufacturing processes and limited clinical validation of circular RNA therapies restrain market growth. Producing high-purity circular RNA requires specialized circularization methods, removal of linear RNA impurities, and stringent quality control procedures. Therapeutic performance depends on RNA stability, translation efficiency, tissue delivery, and appropriate immune responses. Limited human clinical evidence creates uncertainty regarding long-term safety and effectiveness. High development costs, manufacturing scalability challenges, and evolving regulatory expectations further complicate commercialization of emerging circular RNA therapeutic platforms.

Opportunity:

Expansion of circular RNA platforms for in vivo cell engineering and cancer immunotherapy

Expansion of circular RNA platforms for in vivo cell engineering and cancer immunotherapy presents significant growth opportunities. Biotechnology companies are investigating engineered circular RNA molecules capable of expressing therapeutic proteins and reprogramming selected immune cells within the body. Growing research into oncology, autoimmune diseases, and genetic disorders encourages pipeline diversification. Advancements in targeted lipid nanoparticles and RNA translation engineering improve delivery possibilities. Strategic collaborations among pharmaceutical companies, biotechnology developers, and research institutions are expected to accelerate clinical translation.

Threat:

Immunogenicity concerns and competition from established RNA therapeutic technologies

Immunogenicity concerns and competition from established RNA therapeutic technologies pose significant challenges to market development. Circular RNA formulations must demonstrate predictable protein expression, acceptable safety profiles, and controlled biological activity. Unintended immune stimulation, manufacturing impurities, or inefficient tissue targeting may affect clinical outcomes. Established messenger RNA, antisense oligonucleotide, and gene therapy platforms provide competing therapeutic approaches. Intellectual property disputes and regulatory uncertainty surrounding novel RNA modalities may further influence investment decisions, clinical development timelines, and commercialization prospects.

Covid-19 Impact:

The COVID-19 pandemic disrupted biotechnology research through delayed clinical trials, restricted laboratory operations, and interruptions in specialized manufacturing supply chains. However, successful deployment of messenger RNA vaccines accelerated investment in RNA medicine, nucleic acid delivery platforms, and advanced bio manufacturing infrastructure. This momentum encouraged broader exploration of next-generation RNA technologies, including circular RNA therapeutics. Growing familiarity with lipid nanoparticle delivery and RNA manufacturing supported platform development. Post-pandemic expansion of programmable medicine research continues to create opportunities for circular RNA applications.

The protein expression therapeutics segment is expected to be the largest during the forecast period

The protein expression therapeutics segment is expected to account for the largest market share during the forecast period due to growing research into sustained production of therapeutic proteins using engineered circular RNA. These platforms are designed to express selected proteins within target cells while potentially offering improved molecular stability compared with linear RNA. Increasing investigation of enzyme replacement, antibody expression, and regenerative medicine applications supports development. Advancements in circularization efficiency and translation optimization encourage clinical research. Expanding biotechnology investment further strengthens segment prospects.

The lipid nanoparticles (LNPs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the lipid nanoparticles (LNPs) segment is predicted to witness the highest growth rate due to increasing demand for scalable non-viral delivery of circular RNA therapeutics. LNP formulations can protect RNA payloads during administration and facilitate cellular uptake. Growing interest in targeted protein expression and in vivo immune cell engineering encourages delivery platform innovation. Advances in ionizable lipids, tissue targeting, and endosomal escape could expand therapeutic applications. Clinical validation remains essential to establish safety, delivery efficiency, and therapeutic effectiveness.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share due to extensive biotechnology research infrastructure, substantial venture capital investment, and strong pharmaceutical innovation capabilities. The United States and Canada support circular RNA therapeutic development through specialized biotechnology companies, academic research institutions, and advanced manufacturing networks. Growing investment in cancer immunotherapy, cell engineering, and RNA-based medicine encourages regional market development. Strategic partnerships among pharmaceutical organizations and emerging RNA technology developers further strengthen North America's position.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding biotechnology infrastructure, increasing investment in advanced therapeutics, and growing research into nucleic acid medicines. China, Japan, South Korea, India, and Australia are advancing RNA manufacturing capabilities and precision medicine initiatives. Government-supported biotechnology programs and expanding pharmaceutical research activities encourage innovation. Improvements in RNA synthesis, nanoparticle delivery, and clinical development infrastructure are expected to accelerate regional market growth.

Key players in the market

Some of the key players in the Circular RNA-Based Therapeutics Market include Orna Therapeutics, Inc., Sail Biomedicines, Inc., Orbital Therapeutics, Inc., RiboX Therapeutics, Therorna Inc., CirCode Biomed, Circio Holding ASA, Chimerna Therapeutics, Inc., Torque Bio, Inc., Circurna, Circode Therapeutics, Eli Lilly and Company, Merck KGaA, Thermo Fisher Scientific Inc., GenScript Biotech Corporation, Twist Bioscience Corporation, Creative Biogene, and Eterna Therapeutics Inc.

Key Developments:

In October 2026, Circio Holding ASA presented new research at the European Society of Gene and Cell Therapy annual meeting, highlighting its circVec 5.2 platform for enhanced cardiac gene expression and tissue specificity. The development demonstrated continued progress in vector-encoded circular RNA technology and its potential applications in cardiovascular gene therapy and in vivo cellular engineering.

In July 2026, Sail Biomedicines, Inc. announced a strategic collaboration with Johnson & Johnson to develop next-generation in vivo CAR-T therapies for immune-mediated diseases. The collaboration focuses on Sail's Endless RNA technology and targeted nanoparticle platform, designed to enable transient therapeutic protein expression and direct immune cell engineering within the body.

In February 2026, Eli Lilly and Company announced an agreement to acquire Orna Therapeutics, Inc., expanding its capabilities in circular RNA-based medicines and in vivo cell engineering. The transaction includes Orna's engineered circular RNA and lipid nanoparticle technologies, along with its ORN-252 program targeting CD19-positive B cells for potential treatment of autoimmune diseases.

Therapeutic Modalities Covered:

  • Protein Expression Therapeutics
  • In Vivo Cell Engineering Therapeutics
  • Therapeutic Vaccines
  • Regulatory & Non-Coding circRNA Therapeutics
  • Other Therapeutic Modalities

Technologies Covered:

  • In Vitro Synthesized circRNA
  • Vector-Encoded circRNA
  • Engineered Translation-Enhanced circRNA
  • Other Technologies

Delivery Methods Covered:

  • Lipid Nanoparticles (LNPs)
  • Viral Vector-Based Delivery
  • Polymer-Based Nanoparticles
  • Other Delivery Methods

Routes of Administration Covered:

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Local & Intratissue Administration
  • Other Routes of Administration

Applications Covered:

  • Oncology
  • Autoimmune & Inflammatory Diseases
  • Infectious Diseases
  • Genetic & Rare Diseases
  • Cardiovascular & Metabolic Disorders
  • Other Applications

End Users Covered:

  • Hospitals & Specialty Clinics
  • Cancer & Cell Therapy Centers
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Product Code: SMRC41816

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Circular RNA-Based Therapeutics Market, By Therapeutic Modality

  • 5.1 Protein Expression Therapeutics
  • 5.2 In Vivo Cell Engineering Therapeutics
  • 5.3 Therapeutic Vaccines
  • 5.4 Regulatory & Non-Coding circRNA Therapeutics
  • 5.5 Other Therapeutic Modalities

6 Global Circular RNA-Based Therapeutics Market, By Technology

  • 6.1 In Vitro Synthesized circRNA
  • 6.2 Vector-Encoded circRNA
  • 6.3 Engineered Translation-Enhanced circRNA
  • 6.4 Other Technologies

7 Global Circular RNA-Based Therapeutics Market, By Delivery Method

  • 7.1 Lipid Nanoparticles (LNPs)
  • 7.2 Viral Vector-Based Delivery
  • 7.3 Polymer-Based Nanoparticles
  • 7.4 Other Delivery Methods

8 Global Circular RNA-Based Therapeutics Market, By Route of Administration

  • 8.1 Intravenous
  • 8.2 Intramuscular
  • 8.3 Subcutaneous
  • 8.4 Local & Intratissue Administration
  • 8.5 Other Routes of Administration

9 Global Circular RNA-Based Therapeutics Market, By Application

  • 9.1 Oncology
  • 9.2 Autoimmune & Inflammatory Diseases
  • 9.3 Infectious Diseases
  • 9.4 Genetic & Rare Diseases
  • 9.5 Cardiovascular & Metabolic Disorders
  • 9.6 Other Applications

10 Global Circular RNA-Based Therapeutics Market, By End User

  • 10.1 Hospitals & Specialty Clinics
  • 10.2 Cancer & Cell Therapy Centers
  • 10.3 Pharmaceutical & Biotechnology Companies
  • 10.4 Academic & Research Institutions
  • 10.5 Contract Research Organizations (CROs)
  • 10.6 Other End Users

11 Global Circular RNA-Based Therapeutics Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Orna Therapeutics, Inc.
  • 14.2 Sail Biomedicines, Inc.
  • 14.3 Orbital Therapeutics, Inc.
  • 14.4 RiboX Therapeutics
  • 14.5 Therorna Inc.
  • 14.6 CirCode Biomed
  • 14.7 Circio Holding ASA
  • 14.8 Chimerna Therapeutics, Inc.
  • 14.9 Torque Bio, Inc.
  • 14.10 Circurna
  • 14.11 Circode Therapeutics
  • 14.12 Eli Lilly and Company
  • 14.13 Merck KGaA
  • 14.14 Thermo Fisher Scientific Inc.
  • 14.15 GenScript Biotech Corporation
  • 14.16 Twist Bioscience Corporation
  • 14.17 Creative Biogene
  • 14.18 Eterna Therapeutics Inc.
Product Code: SMRC41816

List of Tables

  • Table 1 Global Circular RNA-Based Therapeutics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Circular RNA-Based Therapeutics Market Outlook, By Therapeutic Modality (2023-2034) ($MN)
  • Table 3 Global Circular RNA-Based Therapeutics Market Outlook, By Protein Expression Therapeutics (2023-2034) ($MN)
  • Table 4 Global Circular RNA-Based Therapeutics Market Outlook, By In Vivo Cell Engineering Therapeutics (2023-2034) ($MN)
  • Table 5 Global Circular RNA-Based Therapeutics Market Outlook, By Therapeutic Vaccines (2023-2034) ($MN)
  • Table 6 Global Circular RNA-Based Therapeutics Market Outlook, By Regulatory & Non-Coding circRNA Therapeutics (2023-2034) ($MN)
  • Table 7 Global Circular RNA-Based Therapeutics Market Outlook, By Other Therapeutic Modalities (2023-2034) ($MN)
  • Table 8 Global Circular RNA-Based Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 9 Global Circular RNA-Based Therapeutics Market Outlook, By In Vitro Synthesized circRNA (2023-2034) ($MN)
  • Table 10 Global Circular RNA-Based Therapeutics Market Outlook, By Vector-Encoded circRNA (2023-2034) ($MN)
  • Table 11 Global Circular RNA-Based Therapeutics Market Outlook, By Engineered Translation-Enhanced circRNA (2023-2034) ($MN)
  • Table 12 Global Circular RNA-Based Therapeutics Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 13 Global Circular RNA-Based Therapeutics Market Outlook, By Delivery Method (2023-2034) ($MN)
  • Table 14 Global Circular RNA-Based Therapeutics Market Outlook, By Lipid Nanoparticles (LNPs) (2023-2034) ($MN)
  • Table 15 Global Circular RNA-Based Therapeutics Market Outlook, By Viral Vector-Based Delivery (2023-2034) ($MN)
  • Table 16 Global Circular RNA-Based Therapeutics Market Outlook, By Polymer-Based Nanoparticles (2023-2034) ($MN)
  • Table 17 Global Circular RNA-Based Therapeutics Market Outlook, By Other Delivery Methods (2023-2034) ($MN)
  • Table 18 Global Circular RNA-Based Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 19 Global Circular RNA-Based Therapeutics Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 20 Global Circular RNA-Based Therapeutics Market Outlook, By Intramuscular (2023-2034) ($MN)
  • Table 21 Global Circular RNA-Based Therapeutics Market Outlook, By Subcutaneous (2023-2034) ($MN)
  • Table 22 Global Circular RNA-Based Therapeutics Market Outlook, By Local & Intratissue Administration (2023-2034) ($MN)
  • Table 23 Global Circular RNA-Based Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) ($MN)
  • Table 24 Global Circular RNA-Based Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 25 Global Circular RNA-Based Therapeutics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 26 Global Circular RNA-Based Therapeutics Market Outlook, By Autoimmune & Inflammatory Diseases (2023-2034) ($MN)
  • Table 27 Global Circular RNA-Based Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 28 Global Circular RNA-Based Therapeutics Market Outlook, By Genetic & Rare Diseases (2023-2034) ($MN)
  • Table 29 Global Circular RNA-Based Therapeutics Market Outlook, By Cardiovascular & Metabolic Disorders (2023-2034) ($MN)
  • Table 30 Global Circular RNA-Based Therapeutics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 31 Global Circular RNA-Based Therapeutics Market Outlook, By End User (2023-2034) ($MN)
  • Table 32 Global Circular RNA-Based Therapeutics Market Outlook, By Hospitals & Specialty Clinics (2023-2034) ($MN)
  • Table 33 Global Circular RNA-Based Therapeutics Market Outlook, By Cancer & Cell Therapy Centers (2023-2034) ($MN)
  • Table 34 Global Circular RNA-Based Therapeutics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 35 Global Circular RNA-Based Therapeutics Market Outlook, By Academic & Research Institutions (2023-2034) ($MN)
  • Table 36 Global Circular RNA-Based Therapeutics Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 37 Global Circular RNA-Based Therapeutics Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!